Suggestions
Tony Letai
Professor at Dana-Farber Cancer Institute
Dr. Anthony G. Letai, also known as Tony Letai, is a prominent researcher and physician at Dana-Farber Cancer Institute and Harvard Medical School. He is a Professor of Medicine specializing in cancer research and treatment.12
Education and Career
Dr. Letai received his MD and PhD from the University of Chicago. He completed his residency in internal medicine at Brigham and Women's Hospital, followed by a fellowship in hematology and oncology at Dana-Farber Cancer Institute.1 After his postdoctoral research training in Dr. Stanley Korsmeyer's laboratory, he joined the faculty of Dana-Farber Cancer Institute and Harvard Medical School in 2004.1
Research Focus
Dr. Letai's research primarily focuses on:
- Mechanisms by which cancer cells evade death
- Application of this knowledge to selectively kill cancer cells14
His work has led to collaborations with biotechnology and pharmaceutical companies to develop small-molecule BCL-2 antagonists for clinical trials, particularly targeting chronic lymphocytic leukemia, small-cell lung cancer, and non-Hodgkin's lymphoma.1
Clinical Interests and Expertise
As a physician, Dr. Letai's clinical interests include leukemias. He is board-certified in Medical Oncology since 2001.1
Awards and Recognition
Dr. Letai has received several prestigious awards throughout his career, including:
- Leukemia and Lymphoma Society Scholar Award (2008)
- Elected Member of the American Society of Clinical Investigation (2009)
- V Scholar Award (2005)
- Kimmel Scholar Award (2005)1
Leadership Roles
In addition to his research and clinical work, Dr. Letai serves as the president of The Society for Functional Precision Medicine, which aims to improve patient care through innovative approaches.3
Dr. Letai's LinkedIn username is tony-letai-b9a78bb0, as mentioned in the query.
